A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RO7486967 in Participants with Early Idiopathic Parkinson’s Disease

2023-504412-14-00 Protocol BP43176 Human pharmacology (Phase I) - Other Ended

Start 1 Sep 2022 · End 18 Jul 2024 · Status Ended · 1 EU/EEA countries · 3 sites · Protocol BP43176

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - Other
Status Ended
Participants planned 83
Countries 1
Sites 3

Early Idiopathic Parkinson’s Disease (PD)

Key facts

Sponsor
F. Hoffmann-La Roche AG
Participant type
Patients
Age range
18-64 years, 65+ years
Gender
Male and Female
Therapeutic area
Diseases [C] - Nervous System Diseases [C10]
Trial duration
1 Sep 2022 → 18 Jul 2024
Decision date (initial)
2023-08-22
Transition trial
Yes
Low-intervention
No
Rare-disease indication
No
Vulnerable population
Yes

External identifiers

EU CT number
2023-504412-14-00
EudraCT number
2021-002345-15

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Early Idiopathic Parkinson’s Disease (PD)

VersionLevelCodeTermSystem organ class
20.0 PT 10061536 Parkinson's disease 100000004852

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

F. Hoffmann-La Roche AG

Sponsor organisation
F. Hoffmann-La Roche AG
Address
Grenzacherstrasse 124
City
Basel
Postcode
4058
Country
Switzerland

Scientific contact point

Organisation
F. Hoffmann-La Roche AG
Contact name
Trial Information System - TISL

Public contact point

Organisation
F. Hoffmann-La Roche AG
Contact name
Trial Information System - TISL

Locations

1 EU/EEA country · 3 investigational sites

By country

CountryMS statusPlanned subjectsSites
Netherlands Ended 20 3
Rest of world
United Kingdom, United States
63

Investigational sites

Netherlands

3 sites · Ended
Brain Research Center Amsterdam B.V.
Brain Research Center Amsterdam, Cronenburg 2, 1081 GN, Amsterdam
Brain Research Center Zwolle B.V.
Brain Research Center Zwolle, Dokter Stolteweg 90, 8025 AZ, Zwolle
Stichting Radboud University Medical Center
Center of Expertise for Parkinson & Movement Disorders, Geert Grooteplein Zuid 10, 6525 GA, Nijmegen

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Netherlands 2022-09-01 2024-07-18 2022-09-14 2024-06-06

Oversight and notifications

Regulatory notifications under CTR Articles 38, 52, 53, 54 and 77

Temporary halts 1 · Art. 38 CTR

Temporary halt TH-29540

Halt date
2024-06-13
Member states concerned
Netherlands
Publication date
2024-06-14
Reason
Sponsor decision
Benefit-risk balance changed
No
Treatment stopped
No

Application history

3 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2023-08-04 Netherlands Acceptable
2023-08-22
2023-08-22
2 SUBSTANTIAL MODIFICATION SM-1 2023-09-27 Netherlands Acceptable 2023-12-04
3 NON SUBSTANTIAL MODIFICATION NSM-2 2023-12-20 Netherlands Acceptable 2023-12-20